Aspect Biosystems

Vancouver (BC)

Aspect Biosystems aims to improve the predictive accuracy of the pre-clinical drug discovery process by providing the industry and researchers with the technology to create highly customized physiologically-relevant 3D human tissue models that they can employ in the development of new drugs. Aspect has a long-term vision to expand beyond applications in drug development, by enabling Human Tissues on Demand™ for broad applications in the life sciences including personalized and regenerative medicine.

News about Aspect Biosystems

BioPrinting with Alzheimer’s Stem Cells May Lead to Improved Drug Testing & Treatment

From BioPrinting with Alzheimer’s Stem Cells May Lead to Improved Drug Testing & Treatment –  Alzheimer’s studies give many of us hope, whether we have a relative or friend suffering from the dreaded disease—or simply because we are hoping that a cure will be there if we begin to experience symptoms of the most common and crushing form of dementia. As bioprinting bec...

Read More

Aspect Bio: Printed human body parts could soon be available for transplant

A recent article in the Economist on Aspect Bio –  EVERY year about 120,000 organs, mostly kidneys, are transplanted from one human being to another. Sometimes the donor is a living volunteer. Usually, though, he or she is the victim of an accident, stroke, heart attack or similar sudden event that has terminated the life of an otherwise healthy individual. But a lack of ...

Read More

Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Press Release –   Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets.Through this collaboration, Aspect’s proprietary Lab-on-a-...

Read More

Aspect Biosystems Appoints Spiro Getsios as VP of Tissue Engineering

Press Release –  Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, is pleased to announce the appointment of Spiro Getsios as its new Vice President of Tissue Engineering. Spiro joins Aspect following his role as Director of Biology at GlaxoSmithKline and over 10 years as faculty member at Northwestern University, Feinberg School of Medici...

Read More

Aspect Biosystems CEO Tamer Mohamed Named to Top 40 Under 40

A recent article on Aspect Biosystems CEO –  We are proud to announce that our CEO Tamer Mohamed has been selected by Business in Vancouver for their annual Forty Under 40 Awards. These awards highlight the achievements of 40 of British Columbia's outstanding young entrepreneurs, executives, and professionals. All winners are under 40 years old and have demonstrated exce...

Read More

Johnson & Johnson Partner with Aspect Biosystems to Create 3D Printed Knee

From 3D Printing Industry: Johnson & Johnson Partner with Aspect Biosystems to Create 3D Printed Knee  –  Having announced partnerships with Carbon and HP last year, pharmaceutical company Johnson & Johnson (J&J) have now outlined plans to integrate 3D printing into the development of medical devices. Johnson & Johnson have just revealed a new partnership with Aspect B...

Read More

Synthetic biology: A call for a new culture of responsibility

From Bulletin of the Atomic Scientists –  By Ali Nouri, Shahram Seyedin-Noor (General Partner, Civilization Ventures), December 7, 2018 –  In 1980, the World Health Organization declared the official eradication of smallpox. This was one of modern medicine’s crowning achievements—the elimination of a virus estimated to have killed more than 300 million peop...

Read More